stockrow
Friday 6 November 2026
Export SNOA’s income statement to Excel — free account
Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025.
- Revenue
- +59.6%
- EPS
- +88.2%
- Free cash flow
- +69.3%
Quarter to June 2026, against a year earlier
1.13
0.06
+5.61%
Follow SNOA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 13 | 17 | 19 | 18 | 19 | 13 | 13 | 13 | 14 | 20 | 22 | +4.8% | 24 | 27 | — | +17.5% | |
| Gross margin, % | 44.19 | 43.88 | 46.81 | 45.30 | 35.21 | 31.62 | 33.73 | 37.26 | 38.25 | 37.97 | 38.91 | (6.2) pt | ||||||
| EBT | (13) | (14) | (11) | (4) | (4) | (5) | (5) | (5) | (3) | (3) | (3) | (13.7%) | ||||||
| EBT margin, % | (100.87) | (85.71) | (59.78) | (19.77) | (20.95) | (42.90) | (39.06) | (39.51) | (20.35) | (17.51) | (11.44) | +83.4 pt | ||||||
| Net income | 9 | (14) | (12) | (3) | (4) | (5) | (5) | (5) | (3) | (3) | (2) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 545.74 | 661.03 | 410.61 | 242.60 | 186.66 | 95.16 | 78.21 | 27.99 | 11.51 | 11.60 | 5.70 | (34.8%) | |||||
| Earnings | 390.64 | (568.86) | (255.40) | (44.79) | (39.40) | (38.40) | (30.40) | (10.60) | (2.79) | (1.89) | (1.22) | n/m | ||||||
| Cash flow | (347.53) | (493.61) | (253.61) | (62.12) | (33.85) | (32.01) | (36.25) | (5.27) | (0.07) | (2.34) | (0.67) | (42.6%) | ||||||
| Capex | (16.77) | (7.42) | (2.16) | (2.79) | (1.79) | (1.03) | (1.59) | 0.00 | (0.06) | (0.11) | (0.02) | (42.6%) | ||||||
| Free cash flow | (364.30) | (501.03) | (255.78) | (64.91) | (35.64) | (33.04) | (37.84) | (5.27) | (0.14) | (2.45) | (0.69) | (42.6%) | ||||||
| Book value | 911.96 | 608.17 | 227.03 | 76.10 | 53.74 | 65.54 | 47.01 | 13.49 | 3.55 | 1.84 | 1.71 | (49.8%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | +60.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 3.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | |||||
| P/S | 2.36 | 1.02 | 0.40 | 0.40 | 0.80 | 0.84 | 0.25 | 0.18 | 0.19 | 0.18 | 0.19 | 0.7 | ||||||
| P/B | 1.42 | 1.11 | 0.73 | 1.29 | 2.77 | 1.22 | 0.42 | 0.38 | 0.62 | 1.16 | 0.63 | 1.1 | ||||||
| EV/Sales | 1.03 | 0.44 | 0.23 | 0.27 | 0.67 | 0.35 | 0.00 | (0.03) | (0.18) | 0.07 | (0.05) | 0.3 | ||||||
| EV/FCF | (1.54) | (0.58) | (0.36) | (1.00) | (3.52) | (1.00) | 0.01 | 0.18 | 15.23 | (0.31) | 0.41 | 0.7 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (8) | (12) | (12) | (5) | (3) | (4) | (6) | (2) | 0 | (4) | (3) | (7.8%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (7.7%) | ||||||
| Free cash flow | (9) | (13) | (12) | (5) | (4) | (4) | (6) | (2) | 0 | (4) | (3) | (7.8%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 19 | 13 | 9 | 8 | 9 | 11 | 10 | 9 | 9 | 7 | 11 | (10.3%) | |||||
| Net debt | (17) | (10) | (3) | (3) | (2) | (7) | (3) | (3) | (5) | (2) | (5) | (19.6%) | ||||||
| Shareholders’ equity | 21 | 15 | 10 | 6 | 5 | 9 | 8 | 6 | 4 | 3 | 7 | (19.3%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 47.24 | (64.16) | (70.11) | (22.81) | (26.74) | (30.07) | (29.37) | (31.22) | (24.32) | (22.96) | (13.85) | (70.2) pt | |||||
| ROIC | (188.31) | (156.51) | (98.63) | (174.36) | (70.70) | (174.46) | (62.25) | (88.18) | 0.00 | (220.99) | (69.96) | (32.7) pt | ||||||
| ROE | 58.75 | (77.96) | (91.40) | (41.06) | (71.90) | (72.35) | (61.78) | (68.51) | (65.55) | (84.60) | (42.52) | (143.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 243 | 79 | 63 | 18 | 15 | 11 | 9 | 10 | 8 | 9 | — | (30.7%) | |||||
| Revenue/emp, $m | 0.05 | 0.21 | 0.30 | 1.00 | 1.24 | 1.15 | 1.47 | 1.27 | 1.79 | 2.17 | — | +51.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Sonoma Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | +40.84% (above 0%: growing) | 22.46% | 0.00% | Compare |
| UPC Universe Pharmaceuticals INC | $7.0M | — (loss-making) | 4.1× | −23.98% (below 0%: shrinking) | −110.15% (below 0%: shrinking) | −84.99% (below 0%: shrinking) | 32.57% | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.1M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | |
| GELS Gelteq Limited | $4.9M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| Median of peers | $4.2M | — | — | −25.10% | — | −54.04% | 11.23% | 0.00% |
Pay and ownership Proxy statement filed 28 July 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2026 | 741.12k | 641.73k | 10.91 |
| 2025 | 597.08k | 553.87k | 11.22 |
| 2024 | 726.54k | 697.36k | 17.03 |
Ownership
Directors and executive officers, together
1.02%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement